April 25, 2012 |
Biotech giant Amgen Inc. reported a 5% increase in first-quarter profit, lifted by solid sales overall that helped offset continued weakness for its anemia treatments. The Thousand Oaks company reported profit of $1.18 billion, or $1.48 a share, for the three months ended March 31, compared with net income of $1.13 billion, or $1.20 a share, a year earlier. Revenue for the quarter grew 9% to $4.05 billion. The results topped analysts' expectations for earnings per share of $1.46, excluding one-time items, and sales of $3.94 billion.
February 2, 2012 |
Being anemic could triple an individual's chances of dying in the year following a stroke, researchers said Thursday. Both anemia, which is a lack of healthy red blood cells, and stroke are common conditions among the elderly. Anemia is known to worsen the outcomes of people who have heart attacks. But the new study shows stroke patients are at higher risk, too. Researchers at Yale University School of Medicine looked at 3,750 men treated for an ischemic stroke. Compared with stroke survivors who were not anemic, men with severe anemia had a 3.5 times higher risk of dying while still in the hospital and a 2.5 times greater risk of dying within the first year.
November 25, 2011 |
Sickle cell anemia causes pain, fatigue and delayed growth, all because of a lack of enough healthy red blood cells. And yet genetic mutations that cause it — recessive genes for the oxygen-carrying hemoglobin protein — have survived natural selection because they also seem to provide a natural defense against malaria. Scientists have long known this, and they have long wondered how it worked. In a paper published this month in the journal Science, researchers describe their look into how mutated hemoglobin genes defend their cells against attacks by the malaria parasite Plasmodium falciparum . Study lead author Marek Cyrklaff, an electron microscopist and molecular biologist at Heidelberg University in Germany, explained the results.
November 18, 2011 |
Amgen Inc., aiming to secure future sales of its flagship anemia drug Epogen as potential competition emerges, has reached new supply contracts with the two largest operators of U.S. kidney dialysis clinics. The Thousand Oaks biotechnology company said in a regulatory filing Friday that it had signed a seven-year contract to provide clinic operator DaVita Inc. with at least 90% of its anemia drug needs. Amgen also entered into a multiyear agreement, starting in January, to supply Epogen on a nonexclusive basis to Fresenius Medical Care, according to Amgen spokeswoman Christine Regan.
CALIFORNIA | LOCAL
December 22, 2010 |
Eugene Goldwasser, the biochemist who isolated and purified the anti- anemia protein erythropoietin ? arguably the most important biological drug since insulin ? died Friday at his home in Chicago of kidney failure associated with prostate cancer. He was 88. Erythropoietin, commonly known as EPO, was one of the first blockbuster drugs of the biotechnology industry and was the foundation for the success of Amgen of Thousand Oaks. Yet neither the University of Chicago, where Goldwasser isolated the drug, nor the National Institutes of Health, which funded his work, chose to patent the discovery, and Goldwasser himself never got around to it. "One percent of 1% of the drug's annual revenues would have funded my lab quite handsomely," he later reflected.
October 18, 2010 |
Amgen Inc.'s anemia treatment Aranesp is safe for use in kidney patients whose disease doesn't require dialysis, a U.S. panel found. Outside advisors to the Food and Drug Administration said the treatment shouldn't be withdrawn or limited to a "rescue therapy" after a doubling of stroke risk was seen in a study of 4,000 patients with mild to moderate kidney disease. The panel recommended more studies to better explain which patients benefit from Aranesp and what dosing is ideal.